NCT06464367View on ClinicalTrials.gov

Mechanistic Studies of Psilocybin in Headache Disorders

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Migraine
Interventions
DRUG

Psilocybin

synthetic psilocybin 10 mg (oral)

DRUG

Placebo

synthetic THC 2.5 mg (oral)

Trial Locations (1)

06516

RECRUITING

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
lead

Yale University

OTHER

collaborator

The Wallace Foundation

OTHER

NCT06464367 - Mechanistic Studies of Psilocybin in Headache Disorders | Biotech Hunter | Biotech Hunter